Journal: iScience
Article Title: A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity
doi: 10.1016/j.isci.2025.113314
Figure Lengend Snippet: Comparing the immunogenicity of Sp and aSp in immunocompetent mice, as assessed using different adjuvants (A) ELISA assessment of IgG titers over 18 weeks total post-immunization. The dotted red line represents the time point at which a recall vaccination (third dosing) was conducted in the absence of adjuvant. (B) ELISA assessment of IgG binding to the S1 versus S2 domain of the Sp protein. The sera analyzed in this experiment were derived from samples collected at week 3. (C) ELISA assessment of the different isotypes contained in the sera derived from animals receiving the Sp or aSp vaccine. The samples analyzed were those collected at week 3. (D) Luminex analysis conducted on in vitro re-stimulated splenocytes immunized using the same schema depicted in panel A. Red triangles refer to cytokines/chemokines with depicted differences. (E) A representative schema of the in vitro infectivity assay conducted on HEK cells using Sp-pseudotyped viral particles in the presence of neutralizing antibodies derived from the experiment shown in panel B. (F) The NT 50 results of the infectivity assay conducted in the presence of the neutralizing antibodies. (G) Representative SPR sensorgram in which capture of pre-immune sera (1/100 dilution as negative control) failed to block ACE2 binding to Sp-immobilized sensors. (H) SPR in which 1/100 or 1/1000 dilutions of week 3 neutralizing antibody (nAb)-containing sera #5 inhibited ACE2-Sp binding; the effect was lost when the nAb sera was diluted 1/3000. For experiments in panels A-F: n = 5–6 per group. Data are represented as mean ± SD with ∗ p < 0.05, ∗∗ p < 0.01 and ∗∗∗ p < 0.001. Also see .
Article Snippet: Binding between ACE2 (recombinant human ACE2, ∼105 kDa; Creative Biomart #ACE2-736H) and the Spike protein (Sp; SARS-CoV-2 S protein (D614G) super stable trimer, ∼185 kDa; Acro Biosystems #SPN-C52H3) was monitored using a BIACORE 3000 system (Cytiva Life Sciences).
Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Adjuvant, Binding Assay, Derivative Assay, Luminex, In Vitro, Infection, Negative Control, Blocking Assay
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
